Table 2 Demographic and clinical characteristics and laboratory findings according to hs-CRP groups in non-dialysis ESRD patients
hs-CRP ≤ 3 mg/L (n = 218) | hs-CRP > 3 mg/L (n = 393) | P | |
|---|---|---|---|
Demographics | |||
Age (year), mean ± SD | 55.44 ± 13.55 | 58.96 ± 14.91 | 0.273 |
Sex (male, %) | 124 (56.88%) | 259 (65.90%) | 0.029 |
Etiology of ESRD, n (%) | |||
Diabetic nephropathy | 71 (32.57%) | 125 (31.81%) | 0.857 |
Hypertensive nephropathy | 36 (16.51%) | 65 (16.54%) | 0.993 |
Chronic glomerulonephritis | 65 (29.82%) | 114 (29.01%) | 0.853 |
Other | 28 (12.84%) | 59 (15.01%) | 0.546 |
Undetermined | 18 (8.26%) | 30 (7.63%) | 0.875 |
Blood biochemistry | |||
Urea (mmol/L) | 24.58 ± 10.87 | 27.55 ± 12.37 | 0.068 |
Creatinine (umol/L) | 775.84 ± 343.25 | 845.91 ± 434.48 | 0.083 |
eGFR (ml/min per1.73 m2) | 7.99 (6.33–10.07) | 7.82 (5.36–10.42) | 0.175 |
Hemoglobin (g/L) | 74.30 ± 18.95 | 75.52 ± 19.96 | 0.581 |
Calcium (mg/dL) | 7.97 ± 1.16 | 7.72 ± 1.32 | 0.326 |
Phosphorus (mg/dL) | 5.60 ± 2.31 | 6.04 ± 2.45 | 0.161 |
Ca × P (mg2/dL2) | 43.89 ± 17.10 | 45.98 ± 18.49 | 0.053 |
Intact Parathormone (pg/mL) | 269.87 (175.06–420.21) | 265.18 (138.12–410.00) | 0.370 |
Albumin (g/L) | 36.85 ± 6.08 | 35.31 ± 6.26 | 0.569 |
Ferritin (ng/mL) | 217.60 (100.75–376.80) | 344.30 (192.70–586.88) | < 0.0001 |
Leukocytes (109/L) | 5.98 ± 2.27 | 8.01 ± 3.68 | < 0.0001 |
Neutrophils (109/L) | 4.37 ± 2.01 | 6.28 ± 3.51 | < 0.0001 |
Lymphocytes (109/L) | 1.08 ± 0.53 | 1.04 ± 0.53 | 0.613 |
Platelets (109/L) | 161.70 ± 69.64 | 175.48 ± 74.11 | 0.721 |
Inflammatory markers | |||
hs-CRP (mg/L) | 1.04 (0.445–2.02) | 18.20 (7.4–54.07) | < 0.0001 |
PCT (ng/ml) | 0.42 (0.19–0.80) | 0.69 (0.33–2.03) | 0.034 |
Neutrophil-lymphocyte ratio | 3.96 (2.86–5.85) | 5.74 (3.54–9.01) | < 0.0001 |
Platelet-lymphocyte ratio | 140.65 (110.51–235.17) | 175.28 (116.67–252.26) | 0.022 |
Comorbidity, n (%) | |||
Heart failure | 46 (21.10%) | 90 (22.90%) | 0.685 |
Coronary artery disease | 49 (22.48%) | 66 (16.79%) | 0.105 |
Cerebrovascular disease | 6 (2.75%) | 7 (1.78%) | 0.559 |
Drug use within 1 month, n (%) | |||
Steroid | 2 (0.92%) | 1 (0.25%) | 0.604 |
Cyclophosphamide | 1 (0.46%) | 0 (0.00%) | 0.151 |
Cyclosporine | 1 (0.46%) | 0 (0.00%) | 0.151 |